Increased dopamine availability magnifies nicotine effects on cognitive control: A pilot study

Abstract

Introduction and objectives:

The ability to adapt to new task demands flexibly and to stabilise performance in the presence of distractors is termed cognitive control and is mediated by dopaminergic and cholinergic neurotransmission. We aimed to test the hypothesis that the effect of the cholinergic agonist nicotine on cognitive control depends on baseline dopamine levels.

Methods:

Thirty-eight healthy non-smokers (16 males; M_age=24.05 years) performed a cognitive control task including distractor and switch trials twice. Subjects were split into two parallel groups. One group received 2 g of L-tyrosine two hours prior to testing to manipulate dopamine availability experimentally, while the other group received placebo on both days. One hour later, both groups received in a within-subject design: on one day, a 7 mg nicotine patch; on the other day, a matched placebo. Response time costs for distractor and switch trials served as measures of cognitive stability and flexibility.

Results:

Nicotinic modulation reduced response time costs in switch trials and increased costs in distractor trials (nicotine×condition, p=0.027) with a trend-wise interaction between nicotine, L-tyrosine and trial type (nicotine×L-tyrosine×condition, p=0.068), which was due to stronger nicotine effects under L-tyrosine.

Conclusions:

Our data provide preliminary evidence that nicotine has opponent effects on cognitive stability and flexibility. Subjects who received the dopamine precursor L-tyrosine were more prone to nicotine effects on behaviours, which are improvements in cognitive flexibility at the cost of decreased cognitive stability.

Keywords

L-tyrosine acetylcholine cognition psychopharmacology attention

Introduction

Cognitive control describes the ability to adapt behaviours successfully in response to relevant changes in the environment or current tasks and is often impaired in neurological and psychiatric diseases. It comprises the functions of cognitive stability and flexibility, which are commonly tested by assessing distractor suppression and task switching, respectively. Cognitive control has been associated with the dopaminergic neurotransmitter system and relies on a balance between prefrontal and striatal dopamine signalling, with striatal dopamine being important for flexible updating of behaviour and prefrontal dopamine for cognitive stabilisation (Cools and D’Esposito, 2011; Klanker et al., 2013). There is some evidence for antagonistic changes of flexibility and stability with dopaminergic stimulation (Cools et al., 2001, 2003; Dreisbach and Goschke, 2004). Recent evidence in animals also indicates a possible role of nicotinic acetylcholine receptors (nAChR) in cognitive flexibility. Allison and Shoaib (Allison and Shoaib, 2013) studied the effects of nicotine on cognitive flexibility in rats and demonstrated improved attentional set shifting between visual stimuli of the same dimension (i.e. intra-dimensional) and different dimensions (i.e. extra-dimensional). They suggested that nicotine may mediate these processes via alterations in prefrontal circuitry. In a follow-up study, nicotine and specific α7 and β2* nicotinic agonists improved extra-dimensional set shifting and reversal of the shift dose dependently (Wood et al., 2016). Additionally, the drugs improved ketamine-induced deficits in extra-dimensional set shifting. Similar findings were obtained by Terry et al. (2016) in monkeys, where varenicline, a partial α4β2 and full α7 agonist, reversed ketamine-induced deficits in reversal learning. Human evidence on nicotinic modulation of cognitive flexibility is scarce. In contrast to the results from animal research, one study found a decrease in intra-dimensional set shifting in highly dependent smokers under nicotine (Nesic et al., 2011). A recent study in a larger sample of non-smokers found no evidence for an improvement of response inhibition or interference control after nicotine administration (Ettinger et al., 2017). Inconsistent findings were also obtained with respect to nicotinic modulation of electrophysiological markers of attention- and memory-related cognitive control processes in non-smokers (Evans et al., 2014; Knott et al., 2014).

Baseline performance levels have frequently been found to modulate the effects of nicotine and may account for inconsistent effects in human nicotine studies (Newhouse et al., 2004). Low baseline performance predicted nicotine-induced improvements in attentional reorienting and cognitive control tasks in non-smokers (Behler et al., 2014; Breckel et al., 2015; Petrovsky et al., 2012; Wachter and Gilbert, 2013) and smokers (Hammersley et al., 2016), while high performers were found to deteriorate in a measure of cognitive control under nicotine (Ettinger et al., 2017). Baseline performance in cognitive control tasks may depend on individual dopamine levels (for a review, see Cools and D’Esposito, 2011) For example, individuals with lower prefrontal dopamine levels (Val/VAl carriers of the Val158Met polymorphism of the COMT gene; Chen et al., 2004) perform better in task switching and instrumental reversal learning, thus showing increased cognitive flexibility (Cameron et al., 2018; Krugel et al., 2009). Comparable results were found by Stelzel et al. (2010), who reported that subjects with higher D2 receptor densities and reduced striatal dopamine synthesis (homozygous A2 allele carriers of DRD2/ANKK1-TaqIa polymorphism; Laakso et al., 2005; Ritchie and Noble, 2003) show increased task-switching costs and switching-related neural activity in the prefrontal cortex.

Given the abundance of NAChRs on midbrain dopamine neurons that project to the striatum, nucleus accumbens and prefrontal cortex (Livingstone and Wonnacott, 2009; Wallace and Bertrand, 2013 for review), it is reasonable to assume that dopaminergic and cholinergic mechanisms may interact to adapt behaviours flexibly and that differences in baseline dopamine levels may modulate the effects of cholinergic drugs. Several human pharmacogenetic studies show that polymorphisms in dopamine system genes impact behavioural effects of nicotine in smokers, non-smokers or mixed samples (Ahrens et al., 2015; Gilbert et al., 2005; Jacobsen et al., 2006) and neural effects of nicotine in non-smokers (Bowers et al., 2015). For example, we were previously able to show that nicotine stabilised behaviour by reducing distractor interference only in non-smokers who were C/C carriers of the DRD2 SNP rs6277, a polymorphism which has been suggested to be related to increased striatal dopaminergic tone (Hirvonen et al., 2009; Smith et al., 2017).

To test the hypothesis that increased dopaminergic activity contributes to baseline-dependent nicotine effects in cognitive control, we experimentally manipulated dopamine levels with the dopamine precursor L-tyrosine. L-tyrosine is converted intracellularly by the enzyme tyrosine hydroxylase into the direct dopamine precursor L-DOPA. Tyrosine hydroxylase is the rate-limiting step in dopamine syntheses, as it is regulated by end-product inhibition (Daubner et al., 2012). However, under basal conditions, tyrosine hydroxylase is saturated to only 75% (Carlsson and Lindqvist, 1978). Microdialysis measures of DOPA or dopamine concentration in the rat striatum and medial prefrontal cortex are increased after L-tyrosine application (Brodnik et al., 2012, 2017; During, et al., 1989), indicating that dopamine availability can be increased by additional L-tyrosine. Effective systemic doses of L-tyrosine supplementation in humans vary between 500 and 12 g per day (for a review, see Jongkees et al., 2015). Recently, several studies by Colzato et al. have repeatedly shown cognitive effects on working memory and other tasks of executive function with 2 g of L-tyrosine supplementation (Colzato et al., 2013, 2016; Jongkees et al., 2017; Steenbergen et al., 2015). We therefore used 2 g of L-tyrosine or a respective placebo to manipulate dopamine levels experimentally prior to the application of nicotine or its respective placebo. Subsequently, participants performed a cognitive control task that gauged both flexible shifting between task rules and stable performance in the presence of distractors. Additionally, we included an n-back task following the cognitive control task in order to validate the effectiveness of our L-tyrosine administration, as shown previously (Colzato et al., 2013, 2016; Jongkees et al., 2017). Based on the assumption that the effects of nicotine depend on basal dopamine levels, as suggested by prior pharmacogenetic studies, we hypothesised that we would find stronger nicotinic modulation in the cognitive control task in those subjects receiving L-tyrosine. Whether this modulation is similar or different for distractor processing and task switching is not entirely clear based on the literature and was therefore tested with a three-way interaction of nicotine, L-tyrosine and task condition.

Methods

Participants

Forty-five volunteers were recruited via announcements on the university’s electronic bulletin board. All met the following criteria: healthy non-smokers, normal or corrected vision, between 18 and 35 years old, not on medication (except for contraceptives), no history of neurological or psychiatric disease, body mass index (BMI) between 18 and 26 kg/m², right-handed, no thyroid gland malfunction, not suffering from phenylketonuria and not pregnant. Female volunteers using hormonal contraception were tested when taking the contraceptives (not on pause), and those not taking contraceptives were tested within the first 10 days of their menstrual cycle (follicular phase). One subject accidentally received nicotine on both sessions which led to exclusion of the data. Three subjects did not complete the nicotine session due to side effects such as nausea or dizziness. Further, subjects’ data were excluded from analysis if they showed poor performance in the respective test. Poor performance was defined as an accuracy not being significantly higher than chance level (permutation testing, p=0.05). This led to 38 data sets (15 male; M_BMI=22.99 kg/m²; M_age=23.86 years) for the cognitive control task and 39 data sets (16 male; M_BMI=23.06 kg/m²; M_age=24.05 years) for the n-back task, which were used for statistical analysis.

Drug administration and experimental design

Drug administration was double blinded and placebo controlled. Subjects were randomly assigned to the L-tyrosine group or the placebo group in a between-subject design (see Figure 1 for study design). On both experimental sessions they either received 2 g of L-tyrosine (Bulk Powders, Colchester, UK) or microcrystalline cellulose (placebo; Sigma–Aldrich, St. Louis, MO) dissolved in 330 mL of orange juice. Participants were encouraged to drink the whole glass at a good pace within a few minutes. L-tyrosine was administered two hours prior to the task performance which corresponded to the time point of maximal plasma levels after oral doses of 100 mg/kg or 150 mg/kg L-tyrosine (Glaeser et al., 1979). Nicotine was administered transdermally in a within-subject design using a 7 mg nicotine patch (NiQuitin Clear 7 mg; Omega Pharma, Nazareth, Belgium). A pharmacologically inactive patch served as placebo (DracoHydro ultra; Dr Ausbuettel & Co. GmbH, Dortmund, Germany). The patch was administered one hour prior to the task. With this administration schedule, plasma levels during the task were approximately half of the maximal levels present in smokers after patch application (Rasmussen, et al., 2018). The schedule, however, minimises side effects in non-smokers and has previously yielded behavioural effects (Ahrens et al., 2015; Behler et al., 2014; Breckel et al., 2015; Potter and Newhouse, 2008). The order of patch administration was randomised and balanced. The patch was placed on the subject’s back, directly above the belt line and covered with band-aid to avoid subjects being able to see the patch type during the administration period. Furthermore, patch application and preparation of the drinks were performed in absence of the experimenter by a third person. The combination of a between- and within-subject design was chosen to reduce practice effects due to frequent testing.

Figure 1.

Study design. In total, 45 subjects participated in the study. Due to drop-outs and low performance in task accuracy, the final sample compromised 38 sets for cognitive control task data and 39 sets for n-back task data. While dopaminergic manipulation with L-tyrosine occurred between subjects, cholinergic manipulation was carried out within subjects. Drug application took place double blinded and pseudo randomised.

Volunteers attended three sessions. During the first session, subjects received information about study goals and schedule, and they signed a statement of informed consent. Furthermore, they performed the following neuropsychological paper and pencil or computer-based tests: CANTAB (Cambridge Cognition, 2019) tests: intra-extra dimensional set shift and rapid visual information processing; multiple-choice word test (German verbal intelligence estimate; Schmidt and Metzler, 1992) and impulsive behaviour scale (Kovaleva et al., 2012). Subsequently, they were introduced to the cognitive control task using a short demonstration with a longer inter-stimulus interval. Afterwards, they performed a complete run (25 minutes) of the whole cognitive control task at normal speed to ensure adequate performance levels prior to drug administration. The second session took place one day after the first session. Volunteers were instructed to fast overnight, to refrain from alcohol the evening before and not to drink coffee for at least two hours prior to the appointments. The second session always started at 8:30am or 9:30am. Depending on their group, subjects received either L-tyrosine or placebo. Half an hour later, they were allowed to eat one piece of apple or banana. Another 30 minutes later, either a 7 mg nicotine patch or an inactive placebo was administered in a randomised order. Additionally, subjects were allowed to eat a piece of bread (approximately 50 g of pretzel products) with vegetarian spread. The patch was removed after 50 minutes, right before the subjects started to perform the cognitive control task for approximately 25 minutes. Afterwards, subjects were given a short break for several minutes before performing the n-back task, which was always performed as the second task. The third session took place approximately one week after the second session, and both sessions were identical except for the administered patch (nicotine/placebo). At the end of each session, subjects gave feedback about whether they thought they had received treatment or placebo. Subjects’ well-being was monitored by the experimenter and assessed by means of Bond and Lader (1974) rating scales and cardiovascular measures (heart rate and blood pressure) four times throughout each session. The status was measured before L-tyrosine/placebo administration, before nicotine/placebo patch administration, before nicotine/placebo patch removal and after performing the cognitive control task. The study was conducted in accordance with the Declaration of Helsinki, with ethics approval obtained from the Ethics Committee of the German Psychological Association. All subjects gave their written informed consent and were reimbursed (10€/hour) for their time.

Cognitive control task

We used a sustained attention task with switch and distractor trials to gauge both cognitive flexibility and stability (adapted from Armbruster et al., 2012; see Figure 2). Subjects were presented with digits on the upper part of a computer screen for 900 ms every two seconds and had to indicate with their right hand whether it was odd or even (80% of all trials, ongoing trial). After every three to six trials, this ongoing task was interrupted by one of three conditions (each 6.6%), indicated by the appearance of a second digit in the lower part of the screen which differed in brightness from the upper digit. If the upper digit was brighter (distractor trial), the task rule was unchanged; if the lower digit was brighter (switch trial), subjects had to indicate, using the left hand, whether this number was smaller or larger than five. Assignment of task rules to the hands was counterbalanced across subjects. In the third condition (ambiguous trial), it was impossible to perceive brightness differences visually, although numbers differed by up to 8% in brightness. As the ambiguous condition is not the focus of this article, it will not be analysed further. In total, 720 trials were presented, with a short pause after half of the trials.

Figure 2.

Schematic representation of the cognitive control task. After every three to six trials, the ongoing task condition was interrupted by one of three conditions. In case of a distractor trial, task rules remained equal to the ongoing condition, and the second digit was not of relevance. In case of a switch trial, attention had to be shifted towards the second digit, and another response rule was applied. See text for further details. Note that the ambiguous condition is not of relevance for this paper and is not analysed further here.

N-back task

Subjects performed an n-back task with a two-back and a three-back condition. Three blocks of each condition were presented alternatingly. A stream of single digits (0–9) was displayed on screen, with each stimulus being present for 500 ms, and an inter-stimulus interval jittered between 2400 ms and 3100 ms. Participants responded to targets (33% of the trials) and to non-targets by pressing the index or middle finger of the right hand, respectively. A total of 180 stimuli were presented, and responses could be given within 2000 ms after stimulus onset. The n-back task was primarily included to validate the effectiveness of L-tyrosine in a task, which is well known to rely on prefrontal dopamine (Aalto et al., 2005; Wang, et al., 2004). If L-tyrosine increased dopamine levels, working memory performance should be increased under L-tyrosine. Both paradigms were programmed with Presentation^® software (Neurobehavioural Systems, Berkeley, CA). To ensure that the viewing distance was 50 cm, a chin rest was used. Responses were given via response boxes and recorded with Presentation^®.

Data analysis

Data from the cognitive control task were analysed with respect to response time (JASP v0.9; JASP Team, Amsterdam, The Netherlands). We calculated the mean response time for each condition and response time costs for distractor and switch trials (differences in means between the distractor or switch and the ongoing condition). Statistical analysis focussed on response time costs. Further, neuropsychological test and cognitive control task data from the first session (baseline measurement without drugs; only second half taken due to learning effects in first half) were used to test for differences between groups. Except for switch costs in the cognitive control task, none of the tested variables showed significant differences between groups (see also Supplemental Table S1). Hence, to correct for group differences, reaction time costs were baseline corrected by the use of change scores (response time costs under drug–response time costs at baseline). Corrected response time costs were then entered into one repeated-measures analysis of variance (rmANOVA) with the between-subject factor L-tyrosine (placebo/L-tyrosine) and within-subject factors nicotine (placebo/nicotine) and condition (distractor/switch costs). The rmANOVA with three factors was chosen to enable testing, among other things, whether the dopaminergic modulation of nicotine effects is similar or different for distractor and switch trials. For the n-back task, accuracy values (sum of hits and correct rejections) were calculated separately for the two-back and three-back condition. Accuracy rather than reaction time was analysed, since prior L-tyrosine studies found larger effects on accuracy-based measures (Colzato et al., 2013; Jongkees et al., 2017). Results were analysed usingone rmANOVA with the between-subject factor L-tyrosine (placebo/L-tyrosine) and within-subject factors nicotine(placebo/nicotine) and condition (two-back/three-back). Cardiovascular effects and mood ratings were analysed by calculating the difference between time point 3 (before nicotine/placebo patch take-off) and time point 1 (baseline, before L-tyrosine/placebo administration). These values were then entered into rmANOVAs with the within-subject factor nicotine (placebo/nicotine) and the between-subject factor L-tyrosine (placebo/L-tyrosine).

Results

Cognitive control task

Subjects showed high accuracy with mean values >90%. Table 1 displays response times for ongoing, distractor and switch trials under placebo and nicotine for the placebo and L-tyrosine group. Statistical analyses focussed on switch costs and distractor costs as measures of cognitive flexibility and stability, respectively. There was no main effect of nicotine on response time costs (F(1, 36)=0.117, p=0.735), but there was an interaction between nicotine and condition (F(1, 36)=5.286, p=0.027, η²_p=0.128) driven by reduced switch costs and increased distractor costs under nicotine. Interestingly, we found a trend for a three-way interaction between both drugs and condition (F(1, 36)=3.547, p=0.068, η²_p=0.09). Neither the main effects of condition nor L-tyrosine nor other interactions were significant (p>0.1). To characterise the three-way interaction better, we conducted two separate ANOVAs for the L-tyrosine and placebo group, respectively, with the within-subject factors nicotine and condition. Figure 3 illustrates the effects of nicotine in the L-tyrosine and placebo group, and shows that the effects of nicotine were stronger when subjects received L-tyrosine before nicotine application. In this group, the nicotine application had opposing effects on distractor and switch costs, with increased distractor costs and decreased switch costs (interaction nicotine×condition, F(1, 18)=7.407, p=0.014, η²_p=0.292). In the placebo group, this interaction was not significant (F(1, 18)=0.106, p=0.749). Further, in both groups, the main effect of nicotine remained insignificant (p>0.7). Hence, the effects of nicotine on cognitive control processes are increased under L-tyrosine with opposing effects on cognitive flexibility and stability.

Table 1.

Performance in the cognitive control task: mean response times (in ms) and standard deviations by group and task condition.

Condition	Drug	Placebo group (N=19)		L-tyrosine group (N=19)
		M	SD	M	SD
Ongoing	Placebo	518.29	65.25	515.56	56.54
Ongoing	Nicotine	507.69	68.00	514.34	56.36
Distractor	Placebo	698.19	142.83	713.16	124.21
Distractor	Nicotine	688.61	177.83	737.34	132.00
Switch	Placebo	774.20	132.20	865.04	149.02
Switch	Nicotine	758.88	130.48	831.44	131.71

SD: standard deviation.

Figure 3.

Nicotine-induced modulation of switch and distractor costs in the placebo and L-tyrosine groups. Response time costs were calculated as the difference between response times in distractor or switch trials and response times in the ongoing task. Data were further corrected for baseline differences (drug sessions–baseline session). Therefore, decreased (negative) values represent smaller costs under the drug. Nicotine effects were stronger when dopamine levels were increased with L-tyrosine (right). Note the opposing effects of nicotine on distractor and switch costs. Error bars represent standard deviation.

Working memory task

Accuracy in the n-back task was significantly higher in the two-back condition compared to the three-back condition (main effect condition, F(1, 37)=75.79, p<0.001, η²_p=0.672). The L-tyrosine group showed significantly higher accuracy compared to the placebo group, independent of condition (main effect of L-tyrosine, F(1, 37)=7.13, p=0.011, η²_p=0.162). All other effects, including a nicotine main effect or interactions (also L-tyrosine×nicotine), were not significant (p>0.1). Figure 4 illustrates the main effect of condition and of L-tyrosine; data as a function of all individual conditions are listed in Table 2.

Figure 4.

Improvement of working memory with L-tyrosine. L-tyrosine significantly increased accuracy compared to placebo. Error bars represent standard deviation.

Table 2.

Performance in the working memory task: mean accuracy (in %) and standard deviation by group and task condition.

Condition	Drug	Placebo group (N=19)		L-tyrosine group (N=20)
		M	SD	M	SD
2-back	Placebo	88.60	8.30	93.07	4.37
2-back	Nicotine	87.88	6.49	92.29	3.96
3-back	Placebo	79.99	10.16	85.83	7.56
3-back	Nicotine	82.62	6.57	84.32	5.61

Physiological measures and mood ratings

Analysis of heart rate showed a main effect of nicotine (F(1, 36)=9.174, p=0.005, η²_p=0.203), with a larger increase under nicotine (5.7 beats per minute) compared to placebo (0.4 beats per minute) after drug application. L-tyrosine did not significantly affect heart rate nor did it interact with nicotine (p>0.1). The mean arterial pressure (MAP), which is a combined metric of systolic and diastolic blood pressure (BP) measures (MAP=BP_diast+1/3×(BP_syst−BP_diast) was affected by L-tyrosine (F(1, 36)=4.214, p=0.047, η²_p=0.105) but not by nicotine. There was no interaction between both drugs (p>0.1). Under L-tyrosine, MAP decreased on average by 2.77 mmHG from baseline until the end of patch administration compared to an increase of 5.26 mmHG under placebo (pooled over placebo and nicotine sessions). Subjective ratings of alertness were significantly affected by nicotine (F(1, 36)=6.471, p=0.015, η²_p=0.152). While subjects became more alert from baseline to the end of patch administration under placebo (end of administration minus baseline = −6.377), ratings were unchanged under nicotine (−0.001). Further, nicotine significantly affected contentedness (F(1, 36)=6.882, p=0.013, η²_p=0.16). Contentedness of subjects increased under placebo (−3.281) but decreased with nicotine (1.476). L-tyrosine did not have significant effects nor did it show interactions with nicotine on alertness and contentedness (p>0.1). Nicotine had a significant effect on calmness (F(1, 36)=98.234, p<0.001, η²_p=0.732), with decreased under nicotine (35.29) compared to placebo (−0.409). There was no main effect of L-tyrosine on calmness (p>0.1), but a trend for an interaction with nicotine (F(1, 36)=3.056, p=0.089, η²_p=0.078). An overview of physiological measures and mood ratings is shown in Supplemental Table S2. Additionally, subjects gave feedback at the end of each treatment session on whether they thought they had received placebo or treatment. In the placebo patch sessions, 20/41 subjects correctly identified the placebo patch; in the nicotine session, 26/41 identified that they had received nicotine. A 2×2 chi-square test showed that subjects’ guesses did not significantly differ from an equal distribution (χ²=1.246, p=0.264). Regarding the L-tyrosine treatment, in the first treatment session, 3/19 subjects in the L-tyrosine group compared to 10/19 in the placebo group thought they had received L-tyrosine (χ²=5.729, p=0.017). In the second treatment session, 6/19 subjects in the L-tyrosine group compared to 11/19 in the placebo group thought they had received L-tyrosine (χ²=2.245, p=0.134). Hence, subjects were not able to identify the received substances correctly.

Discussion

We aimed to investigate whether the effects of nicotine on cognitive control are mediated by baseline dopamine levels. We found stronger effects of nicotine in subjects who received L-tyrosine additionally, with a nicotine-induced increase in cognitive flexibility but a decrease in cognitive stability.

Effectiveness of L-tyrosine in increasing baseline dopamine levels

Administration of L-tyrosine, a precursor of the catecholamines dopamine and noradrenaline, increases L-Dopa levels and catecholamine metabolism in the striatum and medial prefrontal cortex in rats (Brodnik et al., 2012, 2017). We used L-tyrosine to manipulate dopamine levels experimentally in human subjects. Even though we cannot exclude that the effects of L-tyrosine were mediated to some extent by an elevation of noradrenaline levels, we would like to underline that only 5% of dopamine is hydroxylated to noradrenaline (Nutt and Fellmann, 1984). Further, L-tyrosine depletion shows much stronger effects on dopamine compared to noradrenaline release (Le Masurier et al., 2014), making a dopaminergic contribution more likely than a noradrenergic contribution.

The effectiveness of L-tyrosine was validated behaviourally with a working memory task, which is well known to rely on levels of prefrontal dopamine measured for example in humans by means of positron emission tomography (PET; Aalto et al., 2005) or in monkeys by means of in vivo single-cell recordings (Wang et al., 2004) or microdialysis (Watanabe et al., 1997). Consistent with our expectations and several prior studies on the effects of acute L-tyrosine on n-back performance (Colzato et al., 2013; Jongkees et al., 2017), we found increased accuracy in the n-back task under L-tyrosine which may be due to increased prefrontal dopamine. In a computational model, Durstewitz and Seamans (2008) showed that an increase in dopamine concentration in the prefrontal cortex leads to a D1-dominated state of prefrontal cortex activation. This is associated with an energy landscape showing deeper attractor states, supporting highly robust representations and stable performance but impairing flexible switching to an alternative behaviour. If we assume that L-tyrosine primarily increased dopamine levels in the prefrontal cortex leading to a D1-dominated state, this would also be consistent with the improved working memory performance in the n-back task. Note that performance on the working memory task after the challenging cognitive control task may have increased the effects of L-tyrosine, which is more effective in cases of dopamine depletion occurring after stress or high cognitive demands (Fernstrom and Fernstrom, 2007; Lehnert et al., 1984; Mahoney et al., 2007). In contrast to the cognitive control task, manipulations of dopamine levels with L-tyrosine did not modulate the effects of nicotine on working memory task performance in our sample of non-smokers. An absence of nicotinic modulation of working memory in non-smokers is consistent with most prior studies (Fisher et al., 2012; Kleykamp et al., 2005; MacQueen and Drobes, 2017; but see Kumari et al., 2003), and a genetic modulation of nicotine effects on working memory was only found in a mixed sample of smokers and non-smokers (Jacobsen et al., 2006). A meta-analysis by Heishman et al. (2010), which reviewed nine different studies, including smoker and non-smoker samples with different application routes, also yielded non-significant effects of nicotine on working memory accuracy. Even though n-back performance also relies on aspects of stability, such as maintenance of representations in working memory and flexibility such as updating, these processes differ from those needed in the cognitive control task. For example, updating demands are much higher in the working memory task, where working memory contents have to be updated in every trial. In contrast, updating in the cognitive control task relates to updating of stimulus–response associations and is only required in a minority of trials – the switch trials. In line with these commonalities and differences of cognitive operations involved, neuroimaging studies also point to common and distinct prefrontal brain areas involved in task switching, stroop and n-back performance (Derrfuss et al., 2004).

Effects of increased baseline dopamine levels on nicotinic modulation of cognitive stability and flexibility

Cognitive stability and flexibility were studied within one task focussing on distractor and switch costs, respectively. Administering L-tyrosine compared to placebo did not affect switch or distractor costs significantly. Nicotine administration reduced switch costs and increased distractor cost compared to placebo. This effect was largely driven by subjects who additionally received L-tyrosine, suggesting an interaction between increased dopamine availability and nicotinic stimulation.

The literature about L-tyrosine effects on flexibility and stability is diverse. A previous study which used the same dose of acute L-tyrosine in female participants reported increased task switching under L-tyrosine (Steenbergen et al., 2015). In contrast to our study, task switches were predictable, and effects of the drug were only present in case of long response–stimulus intervals. The authors suggest that L-tyrosine supports conflict-resolving rather than preparatory components of switching and may act primarily in striatal brain regions. This would be in line with a recent PET/functional magnetic resonance imaging study showing that greater striatal dopamine synthesis capacity is associated with better task switching (Berry et al., 2016). In contrast, studies that compared subjects with polymorphisms that impact on dopamine signalling showed that genotypes associated with presumably lower dopamine levels are better in task switching (Cameron et al., 2018; Colzato et al., 2010; Krugel et al., 2009; Stelzel et al., 2013).

The major aim of this study was to investigate whether experimentally increased dopamine levels may explain interindividual differences in the effects of nicotine on cognitive control. Using PET imaging, Samanez-Larkin et al. (2013) investigated whether the effects of dopaminergic drugs depend on individual differences in dopamine signalling. Since dopamine receptor availability correlated positively with a reduction in switch costs after amphetamine administration, the authors conclude that thalamic and cortical dopamine receptor availability may contribute to such baseline-dependent drug effects on cognitive control. Further, prior pharmacogenetic studies suggest that effects of cholinergic drugs, such as nicotine, could also depend on putative differences in dopamine signalling. For example, subjects who are homozygous for the C allele of the DRD2 SNP rs6277 polymorphism, which presumably increases striatal dopamine signalling (Hirvonen et al., 2009; Smith et al., 2017), showed improved distractor resistance after nicotine (Ahrens et al., 2015). Reduced distractor interference after nicotine administration was also observed in carriers of the A1 allele of the DRD2/ANKK1-TaqIa polymorphism, which leads to lower D2 receptor densities but increased striatal dopamine synthesis (Gilbert et al., 2005; Laakso et al., 2005; Ritchie and Noble, 2003). Nicotine was also shown to modulate resting-state alpha frequency depending on COMT genotype (Bowers et al., 2015). Hence, nicotine seems to increase cognitive stability in subjects with genetically increased striatal dopamine signalling, and it may be speculated that it rebalances fronto-striatal dopamine systems from a flexible to a more stable state. However, increasing dopaminergic neurotransmission with L-tyrosine experimentally yielded the opposite pattern, that is, nicotine induced increases in cognitive flexibility and decreases in stability. Such a discrepancy has recently been reported by Jongkees et al. (2017, 2019) who found L-tyrosine administration but not the COMT polymorphism to impact on the effects of transcranial direct current stimulation on working memory. The magnitude of changes in neurotransmitter levels might be one reason for such a difference between state (i.e. experimental manipulation) and trait (i.e. genotype-dependent baseline) effects on behaviour. Another reason could be the specific modulation of D1 or D2 receptors by polymorphisms of dopaminergic neurotransmission: They are either more related to D2 receptors and striatal functions (DRD2 SNP rs6277 or DRD2/ANKK1-TaqIa polymorphism) or to dopaminergic signalling in prefrontal cortex dominated by D1 receptors (COMT polymorphism). In contrast, systemic L-tyrosine presumably modulates both receptor types and brain areas. Future human neuroimaging studies will need to identify whether L-tyrosine impacts stronger or to the same extent on brain networks implicated in cognitive stability and flexibility. Dissociations of brain networks implicated in dopaminergic modulation of cognitive versus motor flexibility have already been described (Stelzel et al., 2013).

Limitations

Given our sample size of 45, the data can only be seen as a preliminary evidence for the reported cholinergic–dopaminergic interaction. Future studies with larger samples are needed to reproduce and verify our findings. Further, the sample size did not allow us to consider individual differences in genotype which may already lead to differences in dopaminergic or cholinergic tone and signalling. Second, our systemic increase of dopamine availability is rather unspecific in terms of regional or receptor subtype specificity. Additionally, we chose a rather low dose of both drugs and did not adjust for body weight. Finally, the between-subject design may be prone to confounding interindividual differences in cognitive performance.

Conclusions

We here provide first preliminary evidence that experimentally increased dopaminergic signalling increases the effects of nicotine in a cognitive control task. Such combined stimulation of dopaminergic and nicotinic cholinergic receptors had opposing effects on cognitive stability and flexibility. Under increased dopaminergic signalling, nicotine seems only beneficial for flexible adaptation to new task demands. These findings may also be of relevance for nicotinic action in psychiatric disorders with changes in dopamine signalling such as schizophrenia or attention-deficit/hyperactivity disorder. For example, both patient populations show a higher rate of (heavy) smokers compared to healthy controls, and it has been suggested that smoking is used to self-medicate psychiatric symptoms and cognitive deficits (Dalack, et al., 1998; Kumari and Postma, 2005; Van Amsterdam et al., 2018). For both disorders, nicotinic receptors are discussed as potential targets for drug development (Potter et al., 2006, 2014; Tregellas and Wylie, 2019). Our data, however, suggest that improvements in cognitive flexibility with nicotine may come at the expense of increased distraction.

Supplemental Material

SupplementTables – Supplemental material for Increased dopamine availability magnifies nicotine effects on cognitive control: A pilot study

Supplemental material, SupplementTables for Increased dopamine availability magnifies nicotine effects on cognitive control: A pilot study by Stefan Ahrens, Joana Laux, Christina Müller and Christiane M Thiel in Journal of Psychopharmacology

Footnotes

Acknowledgements

The authors would wish to thank C Fiebach for advice on the paradigm.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by a grant from the German Research Foundation DFG TH766/8.

ORCID iD

Stefan Ahrens

Supplemental material

Supplemental material for this article is available online.

References

Aalto

Brück

Laine

, et al. (2005) Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci 25: 2471–2477.

Ahrens

Markett

Breckel

, et al. (2015) Modulation of nicotine effects on selective attention by DRD2 and CHRNA4 gene polymorphisms. Psychopharmacology (Berl) 232: 2323–2331.

Allison

Shoaib

(2013) Nicotine improves performance in an attentional set shifting task in rats. Neuropharmacology 64: 314–320.

Armbruster

Ueltzhöffer

Basten

, et al. (2012) Prefrontal cortical mechanisms underlying individual differences in cognitive flexibility and stability. J Cogn Neurosci 24: 2385–2399.

Behler

Breckel

Thiel

(2014) Nicotine reduces distraction under low perceptual load. Psychopharmacology (Berl) 232: 1269–1277.

Berry

Shah

Baker

, et al. (2016) Aging affects dopaminergic neural mechanisms of cognitive flexibility. J Neurosci 36: 12559–12569.

Bond

Lader

(1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211–218.

Bowers

Smith

De La Salle

, et al. (2015) COMT polymorphism modulates the resting-state EEG alpha oscillatory response to acute nicotine in male non-smokers. Genes Brain Behav 14: 466–476.

Breckel

Giessing

Gieseler

, et al. (2015) Nicotinergic modulation of attention-related neural activity differentiates polymorphisms of DRD2 and CHRNA4 receptor genes. PLoS One 10: e0126460.

10.

Brodnik

Bongiovanni

Double

, et al. (2012) Increased tyrosine availability increases brain regional DOPA levels in vivo. Neurochem Int 61: 1001–1006.

11.

Brodnik

Bongiovanni

Double

, et al. (2017) L-tyrosine availability affects basal and stimulated catecholamine indices in prefrontal cortex and striatum of the rat. Neuropharmacology 123: 159–174.

12.

Cambridge Cognition (2019) CANTAB^® (cognitive assessment software). Available at: www.cambridgecognition.com/cantab (accessed 11 February 2020).

13.

Cameron

IGM

Wallace

Al-Zughoul

, et al. (2018) Effects of tolcapone and bromocriptine on cognitive stability and flexibility. Psychopharmacology (Berl) 235: 1295–1305.

14.

Carlsson

Lindqvist

(1978) Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino-acids in rat brain. Naunyn Schmiedebergs Arch Pharmacol 303: 157–164.

15.

Chen

Lipska

Halim

, et al. (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75: 807–821.

16.

Colzato

Jongkees

Sellaro

, et al. (2013) Working memory reloaded: tyrosine repletes updating in the N-back task. Front Behav Neurosci 7: 1–5.

17.

Colzato

Steenbergen

Sellaro

, et al. (2016) Effects of L-tyrosine on working memory and inhibitory control are determined by DRD2 genotypes: a randomized controlled trial. Cortex 82: 217–224.

18.

Colzato

Van Den Wildenberg

Van Der Does

, et al. (2010) Genetic markers of striatal dopamine predict individual differences in dysfunctional, but not functional impulsivity. Neuroscience 170: 782–788.

19.

Cools

D’Esposito

(2011) Inverted-U–shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry 69: e113–e125.

20.

Cools

Barker

Sahakian

, et al. (2001) Mechanisms of cognitive set flexibility in Parkinson’s disease. Brain 124: 2503–2512.

21.

Cools

Barker

Sahakian

, et al. (2003) L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropsychologia 41: 1431–1441.

22.

Dalack

Healy

Meador-Woodruff

(1998) Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 155: 1490–1501.

23.

Daubner

Wang

(2012) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 508: 1–12.

24.

Derrfuss

Brass

Yves Von Cramon

(2004) Cognitive control in the posterior frontolateral cortex: evidence from common activations in task coordination, interference control, and working memory. Neuroimage 23: 604–612.

25.

Dreisbach

Goschke

(2004) How positive affect modulates cognitive control: reduced perseveration at the cost of increased distractibility. J Exp Psychol Learn Mem Cogn 30: 343–353.

26.

During

Acworth

Wurtman

(1989) Dopamine release in rat striatum: physiological coupling to tyrosine supply. J Neurochem 52: 1449–1454.

27.

Durstewitz

Seamans

(2008) The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biol Psychiatry 64: 739–749.

28.

Ettinger

Faiola

Kasparbauer

, et al. (2017) Effects of nicotine on response inhibition and interference control. Psychopharmacology (Berl) 234: 1093–1111.

29.

Evans

Jentink

Sutton

, et al. (2014) 7mg nicotine patch fails to enhance P300 neural indices of cognitive control among nonsmokers. Pharmacol Biochem Behav 126: 77–82.

30.

Fernstrom

(2007) Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr 137: 1539S–1547S.

31.

Fisher

Daniels

Jaworska

, et al. (2012) Effects of acute nicotine administration on behavioral and neural (EEG) correlates of working memory in non-smokers. Brain Res 1429: 72–81.

32.

Gilbert

Izetelny

Radtke

, et al. (2005) Dopamine receptor (DRD2) genotype-dependent effects of nicotine on attention and distraction during rapid visual information processing. Nicotine Tob Res 7: 361–379.

33.

Glaeser

Melamed

Growdon

, et al. (1979) Elevation of plasma tyrosine after a single oral dose of L-tyrosine. Life Sci 25: 265–271.

34.

Hammersley

Gilbert

Rzetelny

, et al. (2016) Moderation of nicotine effects on covert orienting of attention tasks by poor placebo performance and cue validity. Pharmacol Biochem Behav 149: 9–16.

35.

Heishman

Kleykamp

Singleton

(2010) Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) 210: 453–469.

36.

Hirvonen

Laakso

Någren

, et al. (2009) C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 63: 907–912.

37.

Jacobsen

Pugh

Mencl

, et al. (2006) C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency. Psypharmacology (Berl) 188: 530–540.

38.

Jongkees

Hommel

Kühn

, et al. (2015) Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands-a review. J Psychiatr Res 70: 50–57.

39.

Jongkees

Loseva

Yavari

, et al. (2019) The COMT Val158Met polymorphism does not modulate the after-effect of tDCS on working memory. Eur J Neurosci 49: 263–274.

40.

Jongkees

Sellaro

Beste

, et al. (2017) L-tyrosine administration modulates the effect of transcranial direct current stimulation on working memory in healthy humans. Cortex 90: 103–114.

41.

Klanker

Feenstra

Denys

(2013) Dopaminergic control of cognitive flexibility in humans and animals. Front Neurosci 7: 1–24.

42.

Kleykamp

Jennings

Blank

, et al. (2005) The effects of nicotine on attention and working memory in never-smokers. Psychol Addict Behav 19: 433–438.

43.

Knott

Choueiry

Dort

, et al. (2014) Baseline-dependent modulating effects of nicotine on voluntary and involuntary attention measured with brain event-related P3 potentials. Pharmacol Biochem Behav 122: 107–117.

44.

Kovaleva

Beierlein

Kemper

, et al. (2012) Eine Kurzskala zur Messung von Impulsivität nach dem UPPS-Ansatz: Die Skala Impulsives-Verhalten-8 (I-8). GESIS Working Papers 2012|20, Köln: GESIS. Available at: www.gesis.org/fileadmin/upload/forschung/publikationen/gesis_reihen/gesis_arbeitsberichte/WorkingPapers_2012–20.pdf (accessed 11 February 2020).

45.

Krugel

Biele

Mohr

, et al. (2009) Genetic variation in dopaminergic neuromodulation influences the ability to rapidly and flexibly adapt decisions. Proc Natl Acad Sci U S A 106: 17951–17956.

46.

Kumari

Postma

(2005) Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 29: 1021–1034.

47.

Kumari

Gray

Ffytche

, et al. (2003) Cognitive effects of nicotine in humans: an fMRI study. Neuroimage 19: 1002–1013.

48.

Laakso

Pohjalainen

Bergman

, et al. (2005) The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. Pharmacogenet Genomics 15: 387–391.

49.

Le Masurier

Zetterström

Cowen

, et al. (2014) Tyrosine-free amino acid mixtures reduce physiologically-evoked release of dopamine in a selective and activity-dependent manner. J Psychopharmacol 28: 561–569.

50.

Lehnert

Reinstein

Strowbridge

, et al. (1984) Neurochemical and behavioral consequences of acute, uncontrollable stress: effects of dietary tyrosine. Brain Res 303: 215–223.

51.

Livingstone

Wonnacott

(2009) Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem Pharmacol 78: 744–755.

52.

MacQueen

Drobes

(2017) Validation of the human odor span task: effects of nicotine. Psychopharmacology (Berl) 234: 1–12.

53.

Mahoney

Castellani

Kramer

, et al. (2007) Tyrosine supplementation mitigates working memory decrements during cold exposure. Physiol Behav 92: 575–582.

54.

Nesic

Rusted

Duka

, et al. (2011) Degree of dependence influences the effect of smoking on cognitive flexibility. Pharmacol Biochem Behav 98: 376–384.

55.

Newhouse

Potter

Singh

(2004) Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4: 36–46.

56.

Nutt

Fellmann

(1984) Pharmokinetics of levodopa. Clin Neuropharmacol 7: 35–49.

57.

Petrovsky

Ettinger

Quednow

, et al. (2012) Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy. Psychopharmacology (Berl) 221: 27–38.

58.

Potter

Newhouse

(2008) Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacol Biochem Behav 88: 407–417.

59.

Potter

Dunbar

Mazzulla

, et al. (2014) AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. Biol Psychiatry 75: 207–214.

60.

Potter

Newhouse

Bucci

(2006) Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? Behav Brain Res 175: 201–211.

61.

Rasmussen

Horkan

Kotler

(2018) Pharmacokinetic evaluation of two nicotine patches in smokers. Clin Pharmacol Drug Dev 7: 506–512.

62.

Ritchie

Noble

(2003) Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 28: 73–82.

63.

Samanez-Larkin

Buckholtz

Cowan

, et al. (2013) A thalamocorticostriatal dopamine network for psychostimulant-enhanced human cognitive flexibility. Biol Psychiatry 74: 99–105.

64.

Schmidt

Metzler

(1992) Wortschatztest. Weinheim: Beltz Test.

65.

Smith

Dang

Buckholtz

, et al. (2017) The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum. Transl Psychiatry 7: e1091.

66.

Steenbergen

Sellaro

Hommel

, et al. (2015) Tyrosine promotes cognitive flexibility: Evidence from proactive vs. reactive control during task switching performance. Neuropsychologia 69: 50–55.

67.

Stelzel

Basten

Montag

, et al. (2010) Frontostriatal involvement in task switching depends on genetic differences in D2 receptor density. J Neurosci 30: 14205–14212.

68.

Stelzel

Fiebach

Cools

, et al. (2013) Dissociable fronto-striatal effects of dopamine D2 receptor stimulation on cognitive versus motor flexibility. Cortex 49: 2799–2811.

69.

Terry

Plagenhoef

Callahan

(2016) Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys. Psychopharmacology (Berl) 233: 761–771.

70.

Tregellas

Wylie

(2019) Alpha7 nicotinic receptors as therapeutic targets in schizophrenia. Nicotine Tob Res 21: 349–356.

71.

Van Amsterdam

Van Der Velde

Schulte

, et al. (2018) Causal factors of increased smoking in ADHD: a systematic review. Subst Use Misuse 53: 432–445.

72.

Wachter

Gilbert

(2013) Nicotine differentially modulates antisaccade eye-gaze away from emotional stimuli in nonsmokers stratified by pre-task baseline performance. Psychopharmacology (Berl) 225: 561–568.

73.

Wallace

Bertrand

(2013) Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochem Pharmacol 85: 1713–1720.

74.

Wang

Vijarayaghavan

Goldman-Rakic

(2004) Selective D2 receptor actions on working memory. Science 303: 853–856.

75.

Watanabe

Kodama

Hikosaka

(1997) Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J Neurophysiol 78: 2795–2798.

76.

Wood

Kohli

Malcolm

, et al. (2016) Subtype-selective nicotinic acetylcholine receptor agonists can improve cognitive flexibility in an attentional set shifting task. Neuropharmacology 105: 106–113.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.46 MB